Molecular cytogenetics market seen topping $5.1 billion by 2030

The molecular cytogenetics market is projected to rise from $3.1 billion in 2025 to $5.13 billion by 2030, driven by demand for cancer diagnostics, genetic disorder testing and precision medicine. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Molecular cytogenetics sits at the center of genetic disease testing and cancer diagnostics. - Faster adoption could improve detection of chromosomal abnormalities and support more tailored treatment decisions. - The market's growth signals rising demand for advanced lab tools, genomic analysis and integrated diagnostic workflows.

What happened: - The Business Research Company projected the molecular cytogenetics market will grow from $3.1 billion in 2025 to $3.42 billion in 2026. - The report forecasts the market will reach $5.13 billion by 2030. - The forecast implies a 10.4% CAGR from 2025 to 2026 and a 10.6% CAGR through 2030. - The report was presented as The Business Research Company’s Molecular Cytogenetics Global Market Report 2026. - The company offered a free sample of the market report. - The company also directed readers to view the full molecular cytogenetics market report.

The details: - Molecular cytogenetics covers methods that study the whole genome or specific DNA sequences. - The field examines chromosome structure and function, genome variation, gene expression, evolutionary biology, chromosomal abnormalities and genetic variation. - Medical and tumor genetics are major uses for the technology. - The report linked recent growth to rising genetic disorders, more cancer diagnostic testing, stronger academic and clinical genetics research, better access to lab instruments and greater need for chromosomal abnormality detection. - Future growth is tied to broader personalized medicine adoption, more genomic study investment, expansion in precision oncology diagnostics, higher demand for integrated cytogenetic workflows and advances in imaging and molecular analysis. - Emerging trends include fluorescence in situ hybridization, comparative genomic hybridization, enhanced genomic profiling in oncology, automated cytogenetic platforms, bioinformatics-based interpretation and higher-throughput workflows. - The report said North America held the largest share in 2025. - The report said Asia-Pacific will be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report said new 2026 features include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The report said it also includes key technology and future trend analysis. - The source included contact details for Saumya Sahay at The Business Research Company. - The source listed company social links on LinkedIn, Facebook and X.

Between the lines: - The forecast points to a market moving from research-heavy adoption toward broader clinical use. - The strongest demand appears to come from diseases where earlier and more precise chromosomal analysis can change treatment choices. - Regional growth suggests mature demand in North America and faster capacity-building in Asia-Pacific. - The inclusion of dashboards, scoring tools and hotspot analysis suggests buyers want more decision-ready market data, not just estimates.

What's next: - Wider use of personalized medicine and precision oncology is likely to keep supporting demand. - Adoption of automated platforms and bioinformatics tools could reshape lab workflows over the next several years. - The market's pace will likely track the volume of genetic testing, cancer diagnostics and genomic research investment.

The bottom line: - Molecular cytogenetics is on a steady growth path, with diagnostics, automation and precision medicine driving the next leg of expansion.